2020 年第 4 期 第 15 卷

奥沙利铂联合替吉奥节拍化疗应用于晚期胃癌的临床效果

Clinical effect of metronomic chemotherapy with oxaliplatin plus tegafur, gimeracil and oteracil potassium capsules on advanced gastric cancer

作者：井磊蒋丽媛孙爽

英文作者：Jing Lei Jiang Liyuan Sun Shuang

单位：河北省保定市第一医院肿瘤内科071000

英文单位：Department of Internal Medicine-Oncology Baoding First Hospital Hebei Province Baoding 071000 China

关键词：晚期胃癌；替吉奥；节拍化疗；血管内皮生长因子；基质金属蛋白酶

英文关键词：Advancedgastriccancer;Tegafur,gimeracilandoteracilpotassiumcapsules;Metronomicchemotherapy;Vascularendothelialgrowthfactor;Matrixmetalloproteinase

• 摘要：

• 【摘要】目的    分析奥沙利铂联合替吉奥节拍化疗应用于晚期胃癌的临床效果。方法    选取2016年8月至2018年12月河北省保定市第一医院诊治的130例晚期胃癌患者为研究对象，完全随机分为对照组和观察组，各65例。对照组采用奥沙利铂联合替吉奥常规方法治疗，观察组采用奥沙利铂联合替吉奥节拍化疗。分析2组患者的临床治疗效果、治疗前后血清中血管内皮生长因子（VEGF）和基质金属蛋白酶（MMP）水平的变化及不良反应发生情况。结果    观察组总有效率高于对照组［56.9%（37/65）比47.7%（31/65）］，差异有统计学意义（χ2=1.756，P=0.002）。治疗后，观察组VEGF、VEGF受体、MMP-2、MMP-9水平低于对照组［（20±5）μg/L比（25±4）μg/L、（13.1±2.8）μg/L比（17.8±4.9）μg/L、（10.5±2.9）μg/L比（14.7±3.1）μg/L、（14±3）μg/L比（18±4）μg/L］，差异均有统计学意义（均P<0.05）。观察组消化道反应发生率、骨髓抑制反应发生率低于对照组，差异均有统计学意义（均P<0.05）。结论    奥沙利铂联合替吉奥节拍化疗对晚期胃癌患者临床效果好，不良反应发生率低，且治疗后血清中VEGF及MMP水平明显降低。

• 【Abstract】Objective    To analyze the effect of metronomic chemotherapy with oxaliplatin plus tegafur, gimeracil and oteracil potassium capsules on advanced gastric cancer. Methods    A total of 130 patients with advanced gastric cancer admitted to Baoding First Hospital, Hebei Province from August 2016 to December 2018 were randomly divided into control group and observation group, with 65 cases in both groups. The control group received conventional chemotherapy and the observation group received metronomic chemotherapy with oxaliplatin plus tegafur, gimeracil and oteracil potassium capsules. Clinical efficacy, levels of serum vascular endothelial growth factor(VEGF) and matrix metalloproteinase(MMP) and adverse reactions were analyzed. Results    Total effective rate in observation group was significantly higher than that in control group［56.9%（37/65） vs 47.7%（31/65）］（χ2=1.756, P=0.002）. After treatment, serum levels of VEGF and its receptor, MMP-2 and MMP-9 in observation group were significantly lower than those in control group［（20±5）μg/L vs （25±4）μg/L, （13.1±2.8）μg/L vs （17.8±4.9）μg/L, （10.5±2.9）μg/L vs （14.7±3.1）μg/L, （14±3）μg/L vs （18±4）μg/L］(all P<0.05). Incidences of digestive adverse reactions and myelosuppression in observation group were significantly lower than those in control group(both P<0.05). Conclusion    Oxaliplatin combined with tegafur, gimeracil and oteracil potassium capsules metronomic chemotherapy shows good clinical efficacy and low adverse reactions in treating advanced gastric cancer; serum levels of VEGF and MMP can be significantly reduced after treatment.